Laure Escoubet, CSO, Light Horse Therapeutics
Laure Escoubet, PhD, is the Chief Scientific Officer of Light Horse Therapeutics, a San Diego-based company founded by Ben Cravatt (Scripps Institute), Brian Liau (Harvard) and Nathanael Gray (Stanford).
Laure brings nearly 20 years of experience in drug discovery, building and leading high-performing teams, advancing internal drug discovery programs, and leading the establishment and management of strategic collaborations with biotechnology companies and academic institutions. Prior to joining Light Horse, Laure served as Vice President of Biology at Zentalis Pharmaceuticals and led the Epigenetic Drug Discovery at Celgene/Bristol-Myers Squibb.
Laure completed her postdoctoral training in gene regulation at the University of California, San Diego, in the laboratory of Dr. Christopher K. Glass and earned her PhD in Human Pathophysiology from the University Paul Sabatier in Toulouse, France.
